Every Form 4 that Upstream Bio, Inc. (UPB) has filed with the SEC in the last 12 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A Form 4 covers the transactions officers, directors and large holders report, so if you follow UPB and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full UPB filings page.
Upstream Bio, Inc. reported that CFO and COO Michael Gray sold 853 shares of common stock at $6.10 per share. After this transaction, he directly holds 28,795 shares. According to the disclosure, the sale was automatic under a sell-to-cover policy to satisfy tax withholding on vested restricted stock units.
Upstream Bio, Inc. Chief Executive Officer Everett Rand Sutherland reported an open-market sale of 2,095 shares of common stock at $6.10 per share. According to the filing, these shares were sold automatically under the company’s sell-to-cover policy to satisfy tax withholding obligations tied to vesting restricted stock units, not at the CEO’s discretion. Following this tax-related sale, he directly holds 70,812 shares of Upstream Bio common stock.
Upstream Bio, Inc. Chief Business Officer Adam Houghton reported an automatic sale of common stock tied to tax withholding on vested restricted stock units. He sold 700 shares at $6.10 per share under the company’s sell-to-cover policy, which executes sales without his discretion. After this transaction, he directly holds 23,601 shares of Upstream Bio common stock, so the filing reflects tax-related administration rather than a discretionary change in his investment position.
Upstream Bio, Inc. reported that Chief Medical Officer Aaron Deykin sold 895 shares of common stock at $6.10 per share on June 16, 2026. According to the company’s sell-to-cover policy, these shares were sold automatically to cover tax withholding on vested restricted stock units and were not sold at his discretion.
After this transaction, Deykin directly holds 33,197 shares of Upstream Bio common stock, which includes 1,405 shares previously acquired under the company’s 2024 Employee Stock Purchase Plan.
Upstream Bio, Inc. General Counsel Allison Ambrose reported an automatic sale of common stock tied to tax withholding on vested restricted stock units. On this transaction date, 477 shares were sold at $6.10 per share under a company "sell-to-cover" policy, and Ambrose held 16,048 shares of common stock afterward.
Upstream Bio, Inc. director Marcella K. Ruddy received a grant of 17,096 stock options to buy common stock at an exercise price of $6.69 per share. The options vest in full on the earlier of June 9, 2027 or the next annual stockholder meeting, and she holds 17,096 options after this grant.
Upstream Bio, Inc. director Ronald C. Renaud Jr. received a grant of stock options covering 17,096 shares of common stock. The options have an exercise price of $6.6900 per share and expire on June 8, 2036.
These options vest in full on the earlier of June 9, 2027 or the date of the company’s next Annual Meeting of Stockholders, subject to his continued service. Following this grant, he holds 17,096 derivative securities directly.
Upstream Bio, Inc. director Harold Edward Fleming reported a grant of stock options covering 17,096 shares of common stock, with an exercise price of $6.69 per share and expiration on June 8, 2036. The options vest in full on June 9, 2027 or the next annual stockholder meeting and are held for the benefit of Enavate Sciences, LP, with Mr. Fleming disclaiming beneficial ownership.
Upstream Bio, Inc. director Daniella Beckman received a grant of stock options covering 17,096 shares of common stock. The options have an exercise price of $6.69 per share and expire on June 8, 2036. Following this grant, she holds 17,096 derivative securities directly.
These options will vest in full on the earlier of June 9, 2027 or the date of the company’s next Annual Meeting of Stockholders, provided she continues to serve through the vesting date. This filing reflects a compensation-related award rather than an open-market transaction.
Upstream Bio, Inc. director Liam Ratcliffe reported receiving a grant of stock options. The award covers 17,096 options to buy common stock at an exercise price of $6.69 per share, expiring on June 8, 2036. Following this grant, he holds 17,096 derivative securities of this type directly.
According to the terms, the shares underlying this option will vest in full on the earlier of June 9, 2027 or the date of the company’s next Annual Meeting of Stockholders, provided he continues serving through the vesting date. This is a compensation-related grant rather than an open-market purchase or sale.
Upstream Bio, Inc. director Erez Chimovits reported receiving a stock option grant covering 17,096 shares of common stock. The options have an exercise price of $6.69 per share and expire on June 8, 2036. They vest in full on the earlier of June 9, 2027 or the next Annual Meeting of Stockholders, subject to his continued service. Under an agreement with OrbiMed-affiliated entities, any securities or economic benefits from this award are to be transferred to those OrbiMed funds.
Upstream Bio, Inc. CFO and COO Michael Gray reported an automatic sale of common stock primarily to cover taxes on vested restricted stock units. The transaction involved 852 shares of common stock sold at $9.29 per share. After this sell-to-cover transaction, he directly holds 29,648 common shares. The company has a sell-to-cover policy, and the sale was carried out automatically, not at his discretion.
Upstream Bio, Inc. reported that Chief Medical Officer Aaron Deykin executed an open-market sale of 894 shares of common stock at $9.29 per share on March 16, 2026. According to the company’s sell-to-cover policy, these shares were sold automatically to satisfy tax withholding obligations from vesting restricted stock units and were not sold at his discretion.
Following this tax-related sale, Deykin directly holds 32,687 shares of Upstream Bio common stock.
Upstream Bio, Inc. Chief Executive Officer Everett Rand Sutherland reported an automatic sale of 2,093 shares of common stock at an average price of $9.29 per share. According to the company’s sell-to-cover policy, these shares were sold solely to satisfy tax withholding obligations from vesting restricted stock units.
After this tax-related transaction, Sutherland directly holds 72,907 shares of Upstream Bio common stock. Because the sale was automatic and not at his discretion, it reflects routine tax management rather than a discretionary change in investment stance.
Upstream Bio, Inc. General Counsel Allison Ambrose reported an automatic sale of 475 shares of common stock at $9.29 per share. The company has a “sell-to-cover” policy, so these shares were sold solely to cover tax withholding on vested restricted stock units, not at her discretion. After this transaction, she directly holds 16,525 shares, indicating this was a small, tax-related adjustment to her position rather than a discretionary open-market trade.
Upstream Bio, Inc. Chief Business Officer Adam Houghton reported an automatic sale of 699 shares of common stock at $9.29 per share. According to the company’s sell-to-cover policy, these shares were sold solely to satisfy tax withholding on vested restricted stock units. After this tax-related sale, Houghton directly holds 24,301 shares of Upstream Bio common stock.
Upstream Bio, Inc. reported that its CFO and COO, Michael Gray, received new equity awards on January 2, 2026. He was granted 30,500 shares of Common Stock in the form of restricted stock units (RSUs) at a price of $0 per share, all held as direct ownership after the grant.
The RSUs were granted under the company’s 2024 Stock Option and Incentive Plan and will vest in sixteen equal quarterly installments following January 1, 2026, contingent on his continued service. Gray was also granted a stock option for 91,500 shares of Common Stock with a $27.07 exercise price, which will vest in forty-eight equal monthly installments after January 1, 2026, also subject to continued service.
Upstream Bio, Inc. reported that its Chief Medical Officer, Aaron Deykin, received new equity awards on January 2, 2026. He was granted 32,000 restricted stock units (RSUs) of Common Stock at a grant price of $0, bringing his directly owned Common Stock to 33,581 shares as of that date, which includes 1,581 shares previously acquired under the 2024 Employee Stock Purchase Plan.
The filing also shows a grant of a stock option for 96,000 shares of Common Stock with an exercise price of $27.07 per share, expiring on January 1, 2036. The RSUs vest in sixteen equal quarterly installments after January 1, 2026, and the option vests in forty-eight equal monthly installments after the same date, in each case conditioned on Dr. Deykin’s continued service.
Upstream Bio, Inc. reported that its General Counsel, Allison Ambrose, received new equity awards. On January 2, 2026, she was granted 17,000 shares of Common Stock in the form of restricted stock units at a grant price of $0 under the company’s 2024 Stock Option and Incentive Plan.
The filing also shows a grant of a stock option for 51,000 shares of Common Stock with an exercise price of $27.07 per share, expiring on January 1, 2036. The 17,000 RSUs vest in sixteen equal quarterly installments following January 1, 2026, while the 51,000 options vest in forty-eight equal monthly installments after that date, in each case conditioned on her continued service with the company.